# Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations

> **NCT06517953** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 23 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic
- EGFR G719X
- EGFR L861Q
- EGFR S768I

## Interventions

- **DRUG:** Icotinib
- **DRUG:** Befotertinib

## Key facts

- **NCT ID:** NCT06517953
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-17
- **Primary completion:** 2026-07-30
- **Final completion:** 2027-12-24
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06517953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06517953, "Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06517953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*